---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-012055"
form_type: "8-K"
ticker: "ARMP"
cik: "0000921114"
company_name: "Armata Pharmaceuticals, Inc."
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:55:54.196420+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Armata Q2 operating loss $11.9M; AP-PA02 Phase 2 enrollment complete, topline H2 2024

## Summary
- Q2 2024 operating loss $11.9M vs $9.6M in Q2 2023; R&D $8.5M, G&A $3.4M.
- Cash and equivalents $26.4M as of June 30, 2024, up from $13.5M at Dec 31, 2023.
- Completed enrollment in Phase 2 Tailwind study of inhaled AP-PA02; last patient visit Aug 7, topline data expected H2 2024.
- Received $5.25M non-dilutive DoD grant for AP-SA02 diSArm Phase 2a study.
- Built out cGMP manufacturing facility with five clean rooms, including fill-and-finish suite.

## SEC filing metadata
- accession: 0001558370-24-012055
- form_type: 8-K
- ticker: ARMP
- cik: 0000921114
- company_name: Armata Pharmaceuticals, Inc.
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921114/000155837024012055/0001558370-24-012055-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921114/000155837024012055/armp-20240813x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-012055
- JSON: https://secwatch.observer/filing/0001558370-24-012055.json
- Plain text: https://secwatch.observer/filing/0001558370-24-012055.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.